Nanochap (暖芯迦)

Nanochap operates at the intersection of medical hardware, neurotechnology, and visual prosthetics. Its described focus is more specific than general-purpose health monitoring: it is developing brain-computer interface systems intended to restore visual perception through retinal-pathway and visual-cortex-pathway approaches. The E-BCI approach combines a camera, neural-encoding algorithms, wireless transmission, and a high-density electrode array to stimulate the retina; the V-BCI approach uses electrodes to stimulate the visual cortex, bypassing the retina and optic nerve. The company also develops neural-stimulation and physiological-signal chips, giving it a hardware and chip-development scope alongside system-level work. Its stated progress spans multicenter clinical trials for E-BCI and animal testing for V-BCI, rather than established broad commercial deployment. The company has raised approximately $46.95 million in total, including a $44.04 million round in May 2026 led by Legend Capital. The available company-comparison information does not identify reliable, distinct competitors, so a named peer ranking cannot be substantiated. Its differentiation is best assessed by its dual visual-restoration pathways and in-house capabilities across chips, electrodes, algorithms, and system integration.

Nanochap’s trajectory shows a progression from early financing to larger-scale support for a specialized neurotechnology program. The available financing history includes an angel round in October 2014, subsequent A and A+ rounds, a Series B in 2021, a B+ round in 2024, and a $44.04 million financing event on May 6, 2026. The company’s reported total of $46.95 million is concentrated in that 2026 event and a $2.91 million Series A recorded in December 2018; amounts for several other listed rounds are unavailable. Product development also indicates a move from component capabilities toward integrated systems: its portfolio includes stimulation, vital-sign, and biomolecular-signal chips as well as visual brain-computer interface systems. E-BCI’s reported entry into multicenter clinical trials marks a later-stage development milestone, while V-BCI remains at animal testing, suggesting distinct timelines and technical risks across the two approaches. Hiring across regulatory affairs, supply chain, embedded software, backend engineering, and customer management points to needs spanning product development and commercialization, but does not by itself establish a particular growth rate.